AMPA receptor (antagonist)

Class

Selective non-competitive AMPA receptor antagonist

Notes

Split out of mechanism 351 on 2026-08-06. That row was classed as a positive allosteric modulator but carried perampanel and talampanel, which are non-competitive antagonists — the opposite direction on the same receptor. Perampanel's antagonism is confirmed by the FYCOMPA FDA label (NDA 202834) and Eisai's 2012 launch release.

The AMPA receptor is a subtype of ionotropic glutamate receptor, a channel embedded in neuronal membranes that opens in response to the neurotransmitter glutamate and allows sodium and potassium ions (and, depending on subunit composition, calcium) to flow across the membrane. This flow depolarizes the neuron and is the principal mechanism of fast excitatory signaling throughout the central nervous system. Because excessive or poorly controlled excitatory transmission underlies the abnormal, synchronized neuronal firing seen in seizures, dampening AMPA receptor activity is a rational strategy for seizure control. A non-competitive antagonist achieves this by binding a site on the receptor distinct from where glutamate itself binds, reducing the channel's ability to open regardless of how much glutamate is present at the synapse. This is a meaningful design choice: during a seizure, synaptic glutamate concentrations can be very high, which can overwhelm antagonists that must compete directly with the neurotransmitter for the same binding site. Selectivity for the AMPA receptor over other glutamate receptor subtypes, such as NMDA or kainate receptors, aims to limit the interference to one component of excitatory signaling rather than blunting glutamatergic transmission broadly. This mechanism is relevant primarily to epilepsy and other conditions involving excessive cortical excitability.